C
hronic inflammation defines many organ-specific autoimmune diseases. Initiated after, for example, viral infection (1), inflammation promotes transgression of immune cells from the vascular system into the target organ. Different subtypes of immune cells respond to inflammatory signals, leading to a complex milieu of effector cells involved in either destruction of the target tissue or control of the autoreactive response. Thus, therapeutic intervention of autoimmune diseases requires a detailed knowledge of the relationship between distinct immune cells when exposed to an inflamed environment.
Type 1 diabetes is an autoimmune disease in which the destruction of the insulin-producing ␤-cells in the islets of Langerhans is T-cell mediated (2) . Type 1 diabetes development is genetically and environmentally influenced, and incidences in the developed world increase by 3% per year. The nonobese diabetic (NOD) mouse, a spontaneous murine model for type 1 diabetes, has been invaluable in deciphering its genetic, environmental, and immunological complexities (3) . Studies in NOD mice revealed that before type 1 diabetes detection, islets become infiltrated with CD4
ϩ , CD8 ϩ T-cells, dendritic cells (DCs), and Bcells, with B-cells constituting ϳ60 -70% of intra-islet immune cells (4) . Although both CD4 ϩ and CD8 ϩ T-cells contribute to diabetes, ␤-cell destruction is thought to be due to CD8 ϩ cytotoxic T-cells (CTLs) (5, 6) . The high prevalence of intra-islet B-cells has driven several investigations into their role in type 1 diabetes in NOD mice. To date, these studies have focused on the role of B-cells in the priming and epitope spreading of the anti-islet CD4 ϩ T-cell response (7) (8) (9) (10) (11) , and a central role for B-cells in both these phenomena has been clearly established. Further, B-cell deficiency results in a substantial reduction in the inflammation and a corresponding significant drop in migration of immune cells to the islets. However, the strong association between inflammation, CD8 ϩ T-cells, and type 1 diabetes in NOD mice necessitates investigations into whether B-cells additionally influence isletreactive CTL activity in the inflamed islet independent of their effects on CD4 ϩ T-cell responses. Previously, we described a unique inflammation-based NOD model of type 1 diabetes, RIP TNF␣-NOD (TNF␣-NOD) mice (12) . In such mice, constitutive expression of the diabetes-relevant pro-inflammatory cytokine tumor necrosis factor (TNF)-␣ (13, 14) is restricted to the islet under control of the rat insulin promoter (RIP). TNF␣-NOD mice develop type 1 diabetes rapidly with 100% penetrance of disease by 15 weeks of age. Interestingly, TNF␣-NOD mice share similar characteristics to NOD mice: Diabetes development requires the NOD major histocompatibility complex (MHC) and recessive NOD alleles (15) , and before diabetes, islets become infiltrated sequentially with DCs, B-cells, CD4
ϩ T-cells, and, lastly, CD8 ϩ T-cells (4, 12) . Nevertheless, unlike the NOD mouse, diabetes development is CD4 ϩ T-cell independent, CD8 ϩ T-cell dependent (16) . TNF␣ has divergent roles in type 1 diabetes: Whereas neonatal transgenic expression or systemic injection of TNF␣ accelerates disease, similar manipulations in adult NOD mice protects (12, 14, 17) . The mechanisms behind these divergent outcomes are not completely clear. Nevertheless, we and others (13) have documented that progression to diabetes in NOD mice is characterized by increasing levels of TNF␣ mRNA in the inflamed islet, suggesting TNF␣ may push the diabetic response in unmanipulated NOD mice. These unique features highlighted the attractiveness of using TNF␣-NOD mice to decipher the intricate relationship between B-cells and anti-islet CD8 ϩ T-cells in type 1 diabetes, particularly during chronic inflammation. Here, we show that B-cell-deficient TNF␣-NOD mice have significantly reduced kinetics of disease and provide new evidence for a divergent role for B-cells depending on the stage of disease and the environment where they reside. Whereas in the pancreatic lymph nodes (PLNs), B-cells promote differentiation of CD8 
RESEARCH DESIGN AND METHODS
Mice and genotyping. RIP-TNF␣ NOD mice (N22) and NOD-MT Ϫ/Ϫ (N20) mice have been described elsewhere (10, 12, 16) . TNF␣-MT Ϫ/Ϫ mice were generated by breeding male TNF␣-NOD-MT ϩ/ϩ mice to female NOD-MT Ϫ/Ϫ mice, then intracrossing TNF␣-MT Ϫ/ϩ male mice to female NOD-MT
littermates to create TNF-MT Ϫ/Ϫ and TNF-MT ϩ/ϩ mice littermates for all studies described. TNF␣-MT Ϫ/Ϫ mice were screened by fluorescence-activated cell sorter (FACS) analysis of peripheral blood for B-cells using a rat anti-CD19 Ab (BD Biosciences).
NOD-mIg.MT Ϫ/Ϫ (18) mice were crossed to TNF␣-MT ϩ/ϩ mice, and the resultant heterozygous littermates were intracrossed to generate TNF␣-MT Ϫ/Ϫ , TNF␣-MT ϩ/ϩ , TNF␣-mIg.MT Ϫ/Ϫ , and TNF␣-mIg.MT ϩ/ϩ mice. All mice were housed in specific pathogen-free barrier conditions at Cambridge University Central Biomedical Services. All experimental procedures were conducted under U.K. Government Home Office guidelines. Cell preparations. Islet-residing cells were isolated after collagenase digestion of pancreata as previously described (12) . Cells were isolated from lymph nodes using standard protocols. For purification of CD4 ϩ T-cells, cell suspensions were incubated with rat anti-mouse CD8 (53-6.72) and B220 (RA3-6B2) antibodies (both BD Biosciences), followed by BioMag goat anti-rat IgG magnetic beads (Qiagen). Macrophages and DCs were depleted by incubation of the cell suspension on plastic at 37°C for 30 min. For CD8 ϩ T-cell purification, a rat anti-mouse CD4 Ab (GK1.5; BD Biosciences) was used in place of anti-CD8 Ab. In all cases, cell purity was Ͼ96% as confirmed by FACS analysis.
For purification of intra-islet immune cells for intracellular staining, pancreatic extracts were incubated with rat anti-CD45 Ab (BD Biosciences) and CD45
ϩ cells isolated using a MoFlo cell sorter (Dako Cytomation). Antigen presentation assays. A total of 3 ϫ 10 5 purified T-cells were cultured with 5 ϫ 10 4 irradiated islet-infiltrating antigen-presenting cells (APCs) and islet cells. The assay was pulsed with 1 Ci/well [ 3 H]-methyl thymidine (Factor; Amersham Biosciences UK) for the last 6 h of a 4-day culture, and incorporation of radioactivity was detected using a Top Count ␤-counter (PerkinElmer, Beaconsfield). Intraperitoneal injections. For CD4 ϩ T-cell depletion studies, mice were injected with 0.5 mg purified anti-CD4 (GK1.5; BioExpress). Control mice received 0.5 mg purified rat IgG (Jackson ImmunoResearch). First injections were given at 26, 28, and 30 days of age and then subsequently at 2-week intervals until the end point was reached (diabetic or 30 weeks old). For bromodeoxyuridine (BrdU) studies, mice were injected with 1 mg of BrdU (BD Biosciences) for three consecutive days before analysis. Flow cytometry and intracellular staining. All antibodies/kits were obtained from BD Biosciences unless otherwise stated. Single-cell suspensions were incubated with the appropriately flurochrome-labeled antibodies CD3 (2C11), CD4 (GK1.5), CD8 (53-6.7), CD45 (30-F11), and CD44 (IM7), following Fc receptors blockage. Foxp3 was detected using a Foxp3 staining kit 
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؉ T-CELL SURVIVAL (eBioscience). For BrdU detection, a BrdU detection kit was used following the manufacturer's instructions. All samples were acquired on a FACS Calibur flow cytometer (Becton Dickinson) using Cellquest software and analyzed using FlowJo software (Tree star). For apoptosis studies, an Annexin V-PE kit was used following the manufacturer's protocol. Cytokine measurement. Approximately 1.5 ϫ 10 6 PLN cells or 1 ϫ 10 6 islet T-cells were stimulated with ␣-CD3 and ␣-CD28 Ab (both BD Pharmingen) at 1 g/ml. For the final 4 h of a 24-h incubation period, 1 g/ml of golgi stop (BD Pharmingen) was added. The cells were stained with fluorochrome-labeled anti-CD3, CD8, interferon (IFN)-␥, granzyme B (Caltag Laboratories), or the appropriate isotype control and analyzed by FACS. Diabetes detection. Mice were tested once weekly for glycosuria using Diastix reagent strips (Johnson & Johnson). Diabetes was confirmed after two serum glucose readings of 13.9 mmol/l 48 h apart. Statistical analysis. Comparisons of disease frequencies were performed using the log-rank test. P values Ͻ0.01 were considered significant. For other assays, statistical significance was measured using the Mann-Whitney nonparametric test. P values Ͻ0.05 were considered significant. To illustrate differences in islet-infiltrating CD8
ϩ T-cells in TNF-MT ϩ/ϩ versus TNF-MT Ϫ/Ϫ mice, a nonparametric Kruskal-Wallis test was performed. The P values were corrected using a permutation test permuting the assignment of mice to groups within experiments to allow for potential differences between replicated experiments. P values Ͻ0.001 were considered significant.
RESULTS

B-cells are essential for accelerating inflammationdependent type 1 diabetes.
To assess the importance of B-cells in type 1 diabetes development under potent inflammatory conditions, TNF␣-NOD mice were crossed to B-cell-deficient NOD-MT Ϫ/Ϫ mice, and resultant TNF␣-MT Ϫ/Ϫ NOD (hereafter called TNF␣-MT Ϫ/Ϫ ) mice were monitored for progression to diabetes. TNF␣-MT Ϫ/Ϫ mice had significantly decreased disease kinetics (P ϭ 0.0001) compared to wild-type TNF␣-MT ϩ/ϩ mice, although the overall penetrance of disease was the same (Fig. 1A) . This observation was independent of the sex of the mouse. Nontransgenic littermates were protected from disease as previously reported (data not shown) (10, 19) . Thus, B-cells are essential for accelerating type 1 diabetes in the presence of a strong proinflammatory environment.
B-cell enhancement of disease kinetics was not linked to the secretion of autoantibodies, as has been previously reported (20) . This theory was based on our observation that crossing TNF␣-MT Ϫ/Ϫ mice to transgenic NODmIg.MT Ϫ/Ϫ mice that harbor B-cells carrying a mutation in the secretory component of the Ig gene, thereby preventing Ig secretion but not membrane-anchored expression of Ig (18), efficiently restored disease acceleration in double transgenic TNF␣-mIg.MT Ϫ/Ϫ mice (Fig. 1B ). CD4؉Foxp3؉ Treg cell-independent mechanisms control type 1 diabetes development under chronic inflammatory conditions. Isolated CD4 ϩ or CD8 ϩ T-cells from either TNF␣-MT ϩ/ϩ or TNF␣-MT Ϫ/Ϫ mice efficiently responded to a broad range of islet antigen presented by intra-islet APCs from either strain with equal efficacy (Fig. 1C) . Such responses were antigen specific since T-cells isolated from either strain failed to respond to irradiated splenocytes from TNF␣-MT ϩ/ϩ mice. This suggested priming of the T-cell repertoire and functionality of intra-islet DCs was unimpaired by B-cell deficiency. We, therefore, hypothesized that the disease kinetics in TNF␣-MT Ϫ/Ϫ mice were linked to in situ suppression of T-cell responses by CD4 ϩ Foxp3 ϩ T regulatory (Treg) cells (21) . However, FACS analysis established no significant differences in the percentages of CD4 ϩ Foxp3 ϩ Treg cells between TNF␣-MT ϩ/ϩ and TNF␣-MT Ϫ/Ϫ mice in either the islets or the PLNs (Fig. 2A) . Furthermore, the delayed kinetics of disease in TNF␣-MT Ϫ/Ϫ mice did not require functional CD4
ϩ Foxp3 ϩ Treg cells. This finding was based on observations that administration of anti-CD4 depleting Ab to TNF␣-MT ϩ/ϩ and TNF␣-MT Ϫ/Ϫ mice did not alter disease development in any mouse group with respect to the appropriate isotype control antibody-treated mice (Fig. 2B) . These data suggest that immune-mediated ␤-cell destruction can be controlled independent of the traditional CD4
ϩ Foxp3 ϩ Treg cell suppression.
Intra-islet CD8
؉ T-cells are significantly reduced in the absence of B-cells. Previously we demonstrated that ablation of CD8 ϩ T-cells protected TNF␣-MT ϩ/ϩ mice from developing type 1 diabetes, whereas CD4 ϩ T-cells played a redundant role (16), a finding that was supported by our above observations. Therefore, we focused our attention on the CD8 mice and TNF␣-MT ϩ/ϩ mice. Flow cytometric analysis of lymphocytes from each mouse strain mice revealed a significant decrease (P ϭ 0.0001) in the percentage of intra-islet CD8 ϩ T-cells in TNF␣-MT Ϫ/Ϫ mice compared with TNF␣-MT ϩ/ϩ mice at 8 weeks of age. This time point corresponds to the transition of activated CD8 ϩ T-cells into CTLs (16) . In contrast, we saw no differences in the percentage of intra-islet CD4 ϩ T-cells in TNF␣-MT Ϫ/Ϫ mice compared with TNF␣-MT ϩ/ϩ mice (P ϭ 0.042) (Fig. 3A) . No variation was observed in T-cell proportions within the PLNs of all mice examined (data not shown). To determine whether B-cell ablation results in a general decrease in intra-islet CD8 ϩ T-cell accumulation, we performed time-course studies. We found no significant differences in CD8 ϩ T-cell percentages in the islets of TNF␣-MT Ϫ/Ϫ mice compared with TNF␣-MT ϩ/ϩ mice at 4 and 6 weeks of age (not shown). These data imply that during inflammation, B-cells are central for the accumulation of autoreactive CD8
ϩ T-cells in the target tissue at the CTL generation stage of the disease process.
؉ T-cell turnover and reactivation are independent of B-cells. Using MHC class I tetramerspeptide complexes, we determined that B-cell deficiency did not hinder intra-islet accumulation of CD8 ϩ T-cells specific for two key diabetogenic antigens: insulin and islet-specific glucose-6-phosphate catalytic subunit-related protein (IGRP; data not shown) (6, 22) .
We speculated B-cells to be involved in the later postpriming stage of disease. To test the requirement for B-cells at the intra-islet secondary activation/expansion phase, groups of TNF␣-MT Ϫ/Ϫ and TNF␣-MT ϩ/ϩ mice were injected with the thymidine analogue, bromodeoxyuridine (BrdU), which incorporates into the DNA of proliferating cells. We initially focused on 8-week-old mice, as 8 weeks is the critical age when significant differences in intra-islet CD8 ϩ T-cell levels are apparent in the two strains of mice. Flow cytometric analysis of BrdU ϩ CD8 ϩ T-cells isolated from the islets, PLNs, and control peripheral inguinal lymph nodes from each mouse strain established the greatest percentage of proliferating CD8 ϩ T-cells to be located in the islet fraction in both TNF␣-MT Ϫ/Ϫ and TNF␣-MT ϩ/ϩ mice (Fig. 3B) . Interestingly, although TNF␣-MT Ϫ/Ϫ mice showed significantly decreased turnover of CD8 ϩ T-cells in the lymph nodes compared with TNF␣-MT ϩ/ϩ mice, we detected no differences in the percentage of intra-islet BrdU ϩ CD8 ϩ Tcells between TNF␣-MT ϩ/ϩ and TNF␣-MT Ϫ/Ϫ mice (mean values 12 and 14%, respectively). Furthermore, we could detect no differences in the level of the activation/ memory marker CD44 on intra-islet CD8 ϩ T-cells between the two strains of mice (Fig. 3C) . Examination of 6-weekold mice revealed an identical pattern of cell turnover (not shown). Thus, environmental influences dictate the necessity for B-cell help in the expansion of CD8 ϩ T-cells.
B-cells promote intra-islet survival of activated CD8
؉
T-cells. The above evidence that CD8
ϩ T-cells are significantly decreased in the islets of TNF␣-MT Ϫ/Ϫ mice with respect to TNF␣-MT ϩ/ϩ mice, even though activation and in situ proliferation of CD8 ϩ T-cells are similar between 
FIG. 3. B-cells control intra-islet CD8 ؉ T-cell accumulation at the CTL transition stage. A: Lymphocytes were isolated from the islets of TNF␣-MT
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؉ T-CELL SURVIVAL the two strains of mice, led us to hypothesize that intraislet B-cells directly or indirectly provide survival signals to activated CD8 ϩ T-cells. This hypothesis was supported by evidence that between 7 and 9 weeks of age, the percentage of CD8 ϩ T-cells undergoing apoptosis was significantly higher in the islets of TNF␣-MT Ϫ/Ϫ compared with TNF␣-MT ϩ/ϩ mice (Fig. 4) . This observation was restricted to the CD8 ϩ T-cell population within the islets, as similar analysis of the PLNs revealed no significant differences in the survival of CD8
ϩ T-cells between the two strains of mice. In contrast, we found no significant differences in the survival of intra-islet or PLNderived CD4
ϩ T-cells in TNF␣-MT ϩ/ϩ and TNF␣-MT Ϫ/Ϫ mice. Thus, in the absence of B-cells, it would therefore appear that CD8 ϩ T-cells lack a vital signal required for their prolonged intra-islet survival.
Inflammation bypasses block in CD8؉ T-cell differentiation to CTLs in the islets of TNF␣-MT
؊/؊ mice. The above data clearly state a role for B-cells in the in situ survival of activated CD8 ϩ T-cells. However, we wished to know if this was the only role B-cells played in type 1 diabetes. CD8 ϩ T-cell-mediated destruction of cells requires an activated CD8 ϩ T-cell to transform to a CTL. We therefore determined whether CD8 ϩ T-cells exposed to an inflammatory environment in the presence or absence of B-cells had equal capacity to transform to CTL. Our data suggest that a B-cell role for the transition to CTL is dependent on the environment. IFN␥ ϩ and granzyme B ϩ production at the per cell basis in CD8 ϩ T-cells was significantly reduced in the PLNs of 7-to 9-week-old TNF␣-MT Ϫ/Ϫ mice in comparison to TNF␣-MT ϩ/ϩ mice (Fig. 5) . Interestingly, in inflamed islets, the percentage of CD8 ϩ T-cells that expressed IFN␥ or granzyme B was slightly enhanced in TNF␣-MT Ϫ/Ϫ mice compared with TNF␣-MT ϩ/ϩ mice (Fig. 6A,B) . Nevertheless, the absolute number of intra-islet differentiated CTLs in TNF␣-MT Ϫ/Ϫ mice was decreased between 10 and 30% with respect to the absolute numbers of CTLs in TNF␣-MT ϩ/ϩ mice (Fig. 6C) , a finding that is consistent with the increased apoptosis of CD8 ϩ T-cells at this time point in TNF␣-MT Ϫ/Ϫ mice. These data show B-cells have distinct roles to play in type 1 diabetes development depending on the environment: In the PLNs, they are essential for CTL generation, not survival of CD8
ϩ T-cells; in the islet, alternative mechanisms promote CTL generation. In this latter case, B-cells are central for providing CD8 ϩ T-cell survival signals to maintain high levels of anti-islet CTLs needed to promote type 1 diabetes progression.
DISCUSSION
Understanding the complex interactions of distinct immune cells that invade inflamed target tissues and promote autoimmunity will help decipher the mechanisms that lead to the destruction of the target cell and associated immunopathologies. Here we show for the first time a link between chronic inflammation, B-cells and CD8
ϩ T-cells, and the promotion of type 1 diabetes. We show B-cells play dual roles: In the PLNs, they drive CD8 ϩ T-cell transition to CTL; in the islet, B-cells promote survival of activated 
FIG. 4. B-cells enable prolonged survival of intra-islet CD8 ؉ T-cells. Intra-islet T-cells from TNF␣-MT
CD8
ϩ T-cells at the CTL transition stage, thereby accelerating disease progression.
It is known that B-cells are important in type 1 diabetes development in the NOD mouse at the level of CD4 ϩ T-cell priming to islet antigen GAD (8, 9, 23, 24) . The need for B-cells at the level of the anti-islet CD8 ϩ T-cell, postulated to be the main effectors of ␤-cell destruction in both NOD mice and humans (5, 25, 26) , is not clear and may depend on the specificity of the CD8 ϩ T-cell (27, 28) . Here we used the TNF␣-NOD mouse model of type 1 diabetes, where intra-islet TNF␣-driven chronic inflammation resulted in CD8 ϩ T-cell-dependent, CD4 ϩ T-cell-independent destruction of ␤ cells (16) to determine the importance of the B-cell-CD8 ϩ T-cell relationship in the presence of a normal T-cell repertoire. We showed that TNF␣-MT Ϫ/Ϫ mice had significantly reduced kinetics of type 1 diabetes development compared with TNF␣-MT ϩ/ϩ mice. There are several possibilities as to why the ablation of B-cells significantly decrease the kinetics of diabetes development even in the presence of chronic inflammation: 1) failed priming of the CD8 ϩ T-cell repertoire to islet antigen either directly or indirectly through production of Ig that enables cross-presentation of islet antigens by DCs (29); 2) failed recruitment of CD8 ϩ T-cells to islets; 3) enhanced functionality of CD4 T-cell priming to GAD is defective (11) . This disparity likely reflects our experimental system, for which we used TNF␣-exposed intra-islet APCs and a vast array of islet antigens. Nevertheless, CD4 depletion experiments showed CD4 ϩ T-cells are redundant for disease progression. Surprisingly, CD4
ϩ T-cells also do not contribute to suppression of disease in TNF␣-MT Ϫ/Ϫ mice, a finding that contrasts to studies by Hu et al., where depletion of B-cells in adult NOD mice delays disease, in part, by enhancing CD4
ϩ Treg mechanisms (35) . Our data highlight the unique pathway by which autoreactivity is dampened independent of CD4 ϩ Treg cells, a finding that has potential implications for autoimmune disease linked to failed CD4 ϩ Treg functionality. The answer to why B-cell ablation delays diabetes development seems to lie within the CD8 ϩ T-cell population, with two distinct mechanisms operating depending on the environment investigated. In the PLNs, B-cell deficiency affects the proliferation and differentiation of primed CD8
ϩ T-cells but not their survival. This was evident by similarities in both the numbers of and significant decreases in both BrdU ϩ cells, as well as an absence of IFN␥ and granzyme B production by PLN-residing CD8 mice. However, in inflamed islets, although the ability of CD8 ϩ T-cells to proliferate and differentiate to CTL is not dependent on B-cells, their survival is. This latter hypothesis was based on observations that at 8 weeks of age, when transition of intra-islet CD8
ϩ T-cells to CTL occurs, Ϫ/Ϫ mice may reflect impaired B-cell-DC cooperation for efficient CTL generation due to an absence in BAFF-TACI signaling between the two cell populations (33) . In support of this hypothesis, depletion of B-cells in adult NOD mice results in DCs defective in inducing expansion of and IFN␥ production from both CD4 ϩ BDC2.5 TcR and insulin-specific CD8 ϩ TcR cells (35) .
Nevertheless, in the islets, the proliferation and differentiation of CD8 ϩ T-cells to CTL are not dependent on B-cells. These intriguing findings likely reflect the uniqueness of the inflamed islet environment created by TNF␣, empowering residing DCs to efficiently present islet antigens to CD8 ϩ and CD4 ϩ T-cells and impart the necessary signals for the former to differentiate to CTLs. Indeed, both absolute numbers and activation status of intra-islet DCs were identical in the two strains of mice (not shown). This finding is not surprising considering the potency of TNF␣-associated inflammation to promote DC functionality independent of conventional activation signals (16) . Despite these attributes, it is clear that even in inflamed islets activated DCs alone are not sufficient to enhance progression to diabetes; B-cells are necessary to provide direct, or indirect, survival signals to responding CD8 ϩ T-cells during their transition phase to CTLs. It is interesting that TNF␣-MT Ϫ/Ϫ mice eventually succumb to diabetes, suggesting that in chronically inflamed islets, eventually the need for B-cells is compensated by as yet unknown mechanisms. Future studies resolving the disparity in the roles B-cells play in the PLNs and islets, as well as identification of compensatory pathways that push B-cellindependent assault of ␤ cells, are ongoing. In addition, it will be important to determine whether this B-cell-CD8 ϩ T-cell relationship is operational in NOD mouse models that require CD4 ϩ T-cells to promote diabetes progression. Despite that autoantibody production to islet antigens is a strong predictor of future diabetes development in prediabetic individuals (36, 37) , subscribing a role for B-cells in diabetes development in humans is controversial, principally because of an absence of direct experimental evidence and documentation of a single patient with X-linked agammaglobulinemia developing diabetes (38) . Thus, translating data from inbred strains of NOD mice to genetically diverse humans should be viewed with caution. Nevertheless, clinical trials using rituximab-a humanized anti-human CD20 mAb that depletes B-cells and has been shown to ameliorate T-cell-mediated rheumatic arthritis-are ongoing to test its efficacy to prevent/ reverse type 1 diabetes (www.diabetestrialnet.org). Our data suggest B-cell depletion in patients with clinical manifestations of diabetes but not overt disease could significantly delay disease progression. This hypothesis has recently been substantiated by studies in NOD mice transgenic for human CD20 on B-cells, where B-cell depletion using anti-CD20 Abs during the insulitis phase resulted in significant delay in disease (35) . The emergence of data from the ongoing clinical trials will be imperative for determining the importance of B-cells in human type 1 diabetes development and the validation in translation of the findings from B-cell-deficient NOD mouse models to humans.
